Try our beta test site

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CanBas Co. Ltd.
ClinicalTrials.gov Identifier:
NCT00551512
First received: October 29, 2007
Last updated: March 13, 2017
Last verified: March 2017
  Purpose

The purpose of this research study is to find the answers to the following questions:

  1. What are the highest doses of CBP501 and cisplatin that can be safely administered as consecutive 2-hours and 1-hour infusions every 21 days?
  2. What are the side effects of the combination of CBP501 and cisplatin when given as an infusion every 21 days?
  3. What amount of CBP501 and cisplatin are found in the blood at certain times after it is given?
  4. Are there any substances in your blood or tumor that can tell us about tumor sensitivity to CBP501 and cisplatin?
  5. Will CBP501 given with cisplatin help to treat your cancer?

Condition Intervention Phase
Cancer
Solid Tumors
Drug: CBP501 and Cisplatin
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors

Resource links provided by NLM:


Further study details as provided by CanBas Co. Ltd.:

Primary Outcome Measures:
  • Dose Limiting Toxicity (DLT) during the first two treatment cycles [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Incidence and severity of adverse events and laboratory abnormalities, graded according to NCI-CTCAE version 3.0 [ Time Frame: During and at end of study ]
  • Occurrence of Serious Adverse Events (SAEs) [ Time Frame: During and at end of study ]
  • Occurrence of discontinuations due to treatment-related adverse events [ Time Frame: At end of study ]
  • Serum concentrations of CBP501 and total and ultrafiltrate platinum to determine, via non-compartmental methods, Cmax, AUC, lz, t½, Cl and Vss. [ Time Frame: During and at end of study ]
  • Evaluation of the relationship between administered dose and plasma pharmacokinetic parameters for CBP501 and cisplatin [ Time Frame: During and at end of study ]
  • Objective tumor response assessed according to RECIST [ Time Frame: During and at end of study ]
  • Time to progression [ Time Frame: During and at end of study ]

Enrollment: 48
Study Start Date: November 2006
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CBP501 and Cisplatin
Dose escalation study
Drug: CBP501 and Cisplatin
CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
Other Name: CBP501 and CDDP

Detailed Description:

9.1 23BOverall Study Design and Plan This was an open-label, multicenter, dose-escalation and pharmacokinetic Phase I study of CBP501 and cisplatin administered as consecutive IV infusions according to a once-every-3-weeks schedule in patients with advanced solid tumors refractory to standard therapy. The study was conducted in three US centers. During the course of the study, an amendment was introduced (#3, October 17th, 2007; see section X9.8X) to allow administration of a unique dosing of single agent CBP501 prior to the initiation of combination therapy to enable completion of the pharmacokinetic (PK) characterization of single agent CBP501. Pharmacodynamic analysis involving phosphoserine 216 evaluations was also removed. See section X16.1.1X for copies of the protocol and all protocol amendments. With 8 additional patients included at the recommended dose (at DL6), it was decided to stop all PK and CTC sampling (and therefore the day-7 CBP501 alone infusion), as sufficient information had been retrieved. In addition, based on evidence of efficacy observed in ovarian cancer patients, a further 10 ovarian and 4 endometrial cancer patients were to be included at the recommended dose; these patients were to be assessed for DLT to confirm the identification of the MTD.

Case Report Forms were used to collect the data, and data management was carried out by AAIOncology. All laboratory data and Investigator observations were be transcribed into the CRF. ECG, U/S, MRI and CT scans were to be reported in summary in the CRF. The original reports, traces and films were to be retained by the Investigators for future reference. See section X16.1.2X for a sample CRF.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent obtained prior to initiation of any study-specific procedures.
  • Pathologically-confirmed, locally advanced or metastatic solid tumors, refractory to standard therapy.
  • Male or female patients aged 18 years or over.
  • ECOG Performance Status (PS): 0-1.
  • Life expectancy > 3 months.
  • Previous anticancer treatment must be discontinued at least 3 weeks prior to first dose of study treatment (6 weeks for mitomycin C; 6 weeks for anti-androgen therapy if discontinued prior to treatment initiation, with the exception of 8 weeks for bicalutamide).
  • Adequate organ function including the following:
  • Bone Marrow: absolute neutrophil count (ANC) ³ 1.5 x 109/L, platelet count ³ 100 x 109/L, hemoglobin ³ 9 g/dL
  • Hepatic: Bilirubin £ 1.5 x the upper limit of normal (ULN), aspartate transaminases (AST/SGOT) and alanine transaminases (ALT/SGPT) £ 2.5 x ULN (or ≤ 5 x ULN if liver metastases are present), INR £ 1.5 x ULN
  • Renal: Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ³ 70 mL/min (calculated according to the Cockroft and Gault formula)
  • Metabolic: serum potassium, calcium and magnesium ³ lower limit of normal (LLN)
  • Creatine phosphokinase isoenzymes: CPK-MB, CPK-MM ≤ ULN
  • Troponin I serum level within normal values
  • Female patients of child-bearing potential must have a negative pregnancy test and use at least one form of contraception as approved by the investigator for 4 weeks prior to the study and 4 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as: "All female patients unless they are post-menopausal for at least one year or are surgically sterile".
  • Male patients must use a form of barrier contraception approved by the investigator during the study and for 4 months after the last dose of study drug.
  • Ability to co-operate with the treatment and follow-up.

Exclusion Criteria:

  • Radiation therapy to more than 30% of the bone marrow prior to entry into the study.
  • Prior chemotherapy with nitrosoureas or high dose carboplatin (AUC > 6 mg/mL), prior mitomycin C cumulative dose ³ 25 mg/m², prior bone marrow transplant or intensive chemotherapy with stem cell support.
  • Presence of any serious concomitant systemic disorders incompatible with the study (e.g. uncontrolled congestive heart failure, active infection, etc.).
  • Any previous history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry.
  • Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance.
  • Evidence of peripheral neuropathy > grade 1 according to NCI-CTCAE Version 3.
  • Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry.
  • Pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception.
  • Known HIV, HBV, HCV infection.
  • Active CNS metastasis: patients with a history of CNS metastases will be eligible if they have been treated and are stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on a stable dose of steroids for > 1 week prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00551512

Locations
United States, Arizona
Scottsdale Clinical Research Institute
Scottsdale, Arizona, United States, 85258
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Nevada
Nevada Cancer Institute
Las Vegas, Nevada, United States, 89135
Sponsors and Collaborators
CanBas Co. Ltd.
Investigators
Study Director: Ernesto Wasserman, MD AAIOncology
  More Information

Publications:

Responsible Party: CanBas Co. Ltd.
ClinicalTrials.gov Identifier: NCT00551512     History of Changes
Other Study ID Numbers: CBP 06-01
Study First Received: October 29, 2007
Last Updated: March 13, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by CanBas Co. Ltd.:
cancer
solid tumors

Additional relevant MeSH terms:
Cisplatin
Antineoplastic Agents

ClinicalTrials.gov processed this record on March 29, 2017